natgillin/translations-raw huggingface dataset:
a condom (with spermicide, if available) a diaphragm (with spermicide, if available).
kondom (s spermicidom, če je na voljo), diafragmo (s spermicidom, če je na voljo).
A condom is required during and for 3 months after treatment with enzalutamide if the patient is engaged in sexual activity with a pregnant woman.
Če ima bolnik spolne odnose z nosečo žensko, morata med zdravljenjem in še 3 mesece po zdravljenju z enzalutamidom uporabljati kondome.
A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released
Končni potrditveni test jakosti je seronevtralizacijski test pri podganah ob sprostitvi serije.
a Confirmed complete cytogenetic response (cCCyR) is defined as a response noted on two consecutive occasions (at least 28 days apart). b Complete cytogenetic response (CCyR) is based on a single bone marrow cytogenetic evaluation. c Major molecular response (at any time) was defined as BCR-ABL ratios ≤ 0.1% by RQ-PCR in peripheral blood samples standardised on the International scale.
a Potrjen popolni citogenetski odziv (cCCyR) je opredeljen kot odziv, opažen pri dveh zaporednih vrednotenjih (z vsaj 28-dnevnim razmikom). b Popolni citogenetski odziv (CCyR) temelji na enem citogenetskem vrednotenju kostnega mozga. c Dober molekularni odziv (ob katerem koli času) je bil opredeljen kot razmerje BCR-ABL ≤ 0,1% z RQ-PCR v vzorcu periferne krvi, standardiziranem po mednarodni lestvici.
A connection between visceral lipomatosis and protease inhibitors (PIs) and lipoatrophy and NRTIs has been hypothesised.
Domnevajo, da obstaja povezava med visceralno lipomatozo in zaviralci proteaz (PI – protease inhibitor) ter lipoatrofijo in NRTI-ji.
A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.
Posledica farmakodinamike hitrodelujočih insulinskih analogov je, da se hipoglikemija – če do nje pride – lahko pojavi v krajšem času po injiciranju kot pri topnem humanem insulinu.
A consistent and standard inhalation technique should be employed to ensure both optimal and consistent drug delivery.
Uporabljati morajo dosledno in standardno tehniko inhaliranja, s čimer bodo zagotovili tako optimalni kot vedno enak vnos zdravila.
A consistent improvement (ramucirumab plus docetaxel vs placebo plus docetaxel) was observed in important subgroups for PFS and OS.
Konsistentno izboljšanje (ramucirumab in docetaksel v primerjavi s placebom in docetakselom) so opazili v pomembnih podskupinah za preživetje brez poslabšanja bolezni in celokupno preživetje.
A consistent response to treatment with tenofovir disoproxil 245 mg (as fumarate) was seen regardless of baseline HIV-1 RNA and CD4 count.
Ne glede na začetno vrednost HIV-1 RNA in števila CD4 je bil odziv na zdravljenje z 245 mg dizoproksiltenofoviratom (v obliki dizoproksiltenofovirijevega fumarata) enak.
a contraceptive depot injection an intra-uterine device (“the coil” or IUD) surgical sterilisation.
kontracepcijsko depo injekcijo, maternični vložek (spiralo ali IUV), kirurško sterilizacijo.
a control = All patients had active RA despite treatment with stable methotrexate doses for 6 months prior to enrolment and were to remain on stable doses throughout the study.
a Kontrolna skupina: Vsi bolniki so imeli aktivni revmatoidni artritis kljub zdravljenju s stalnimi odmerki metotreksata že 6 mesecev pred vključitvijo v študijo; te odmerke so prejemali še naprej ves čas študije.
A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with Betmiga; however, Betmiga should be administered with caution to patients with clinically significant BOO.
V kontrolirani klinični študiji pri bolnikih z BOO, zdravljenih z zdravilom Betmiga, ni bilo dokazanega povečanega zadrţevanja urina; vendar pa je treba pri bolnikih s klinično pomembnim BOO zdravilo Betmiga uporabljati previdno.
A copy of the SPC
Izvod SPC-ja
A core text as agreed by the Rapporteur
osnoven tekst, kot je bil dogovorjen s poročevalcem
A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed.
Opazili so korelacijo med celotno izpostavljenostjo zdravilu deljeno z vrednostjo MIC (AUC/MIC) in kliničnim izidom.
A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed.
Opazili so korelacijo med količnikom celotne izpostavljenosti zdravilu in vrednosti MIC (AUC/MIC) ter kliničnim izidom.
a corticosteroid - such as dexamethasone and a ‘5-HT3 antagonist’ - such as ondansetron
kortikosteroid – na primer deksametazon in antagonist 5-HT3 – na primer ondansetron
A cotton ball.
kos vate,
A course of MabThera consists of two 1000 mg intravenous infusions.
Cikel zdravljenja z zdravilom MabThera je sestavljen iz dveh 1.000 mg intravenskih infuzij.
A course of therapy is defined as three intravenous injections of Pedea given at 24 hour intervals.
Zdravljenje z zdravilom Pedea sestoji iz treh intravenskih injekcij zdravila Pedea, danih v 24-urnih intervalih.
A course of therapy is defined as three intravenous injections of Pedea given at 24-hour intervals.
Zdravljenje z zdravilom Pedea sestoji iz treh intravenskih injekcij, apliciranih v 24-urnih intervalih.
A course of vaccination should include at least three injections of HBVaxPro.
Cikel cepljenja mora obsegati vsaj tri injekcije zdravila HBVaxPro.
A course of vaccination should include three injections.
Ciklus cepljenja mora obsegati vsaj tri injekcije.
A cross-study analysis in 217 patients with advanced solid tumours indicated that gender did not affect the pharmacokinetics of HYCAMTIN capsules to a clinically relevant extent.
Medštudijska analiza 217 bolnikov z napredovalimi čvrstimi tumorji je pokazala, da spol ne vpliva klinično pomembno na farmakokinetiko kapsul HYCAMTIN.
A cross-study analysis in 217 patients with advanced solid tumours indicated that gender did not affect the pharmacokinetics of HYCAMTIN capsules to a clinically relevant extent.
Navzkrižna analiza študije 217 bolnikov z napredovalimi čvrstimi tumorji je pokazala, da spol ne vpliva klinično pomembno na farmakokinetiko kapsul HYCAMTIN.
A cumulative overview of all events reported during the period, stratified according to type of reporter (patient or health care professional), seriousness, expectedness, and whether spontaneous or solicited.
Kumulativen pregled vseh dogodkov, poročanih med obdobjem, razvrščenih glede na tip poročevalca (pacient ali zdravstveno osebje), resnost, pričakovanost in spontanost ali ne- spontanost.
A cumulative review of bronchoconstriction was also conducted.
Opravljen je bil tudi kumulativni pregled bronhokonstrikcije.
A cut-off of >2% was applied
Uporabljen je bil mejni delež > 2 %.
A CYP3A4 inducer, rifampicin (600 mg daily), reduced tadalafil AUC by 88 % and Cmax by 46 %, relative to the AUC and Cmax values for tadalafil alone (10 mg).
Induktor CYP3A4, rifampicin (600 mg dnevno), je zmanjšal AUC tadalafila za 88 % in Cmax za 46 % v primerjavi z vrednostmi AUC in Cmax za tadalafil sam (10 mg odmerek).
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88 %, relative to the AUC values for tadalafil alone (10 mg).
Induktor CYP3A4, rifampicin, je AUC tadalafila zmanjšal za 88 % v primerjavi z vrednostmi AUC za sam tadalafil (10 mg odmerek).
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88 %, relative to the AUC values for tadalafil alone (10 mg).
Induktor CYP3A4, rifampicin, je AUC tadalafila zmanjšal za 88 % v primerjavi z vrednostmi AUC za sam tadalafil (10 mg).
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10 mg).
Induktor CYP3A4, rifampicin, je AUC tadalafila zmanjšal za 88% v primerjavi z vrednostmi AUC za sam tadalafil (10 mg odmerek).
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10 mg).
Induktor CYP3A4, rifampicin, je AUC tadalafila zmanjšal za 88% v primerjavi z vrednostmi AUC za sam tadalafil (10 mg).
A daily dose from 400 mg per day (2 tablets) to 1200 mg per day (6 tablets) taken orally in 2 to 3 divided doses may be required to restore your normal cortisol levels.
Za ponovno vzpostavitev normalnih ravni kortizola bo morda potreben dnevni odmerek od 400 mg na dan (2 tableti) do 1200 mg na dan (6 tablet) peroralno, ki se vzame v 2 do 3 ločenih odmerkih.
A daily increase of oestradiol levels of 40- 100% is considered to be optimal.
40-100 % dnevno povečanje plazemske koncentracije estradiola šteje za optimalnega.
A dark yellow film-coated, tapered oblong shaped, biconvex tablet marked with “ME” on the left of the score and “10” on the right of the score on one side of the tablet and a score on the other side.
Temno rumene, stožčaste, podolgovate, bikonveksne filmsko obložene tablete, označene z "ME" levo in "10" desno od razdelilne zareze na eni strani tablete ter razdelilno zarezo na drugi strani.
a Day 169 Last Observation Carried Forward (LOCF) for patients treated in Period C b As observed
a Na 169. dan prenos zadnje opažene vrednosti naprej (LOCF-Last Observation Carried Forward) za bolnike, ki so se zdravili v obdobju C b opažene vrednosti
A decision about using this vaccine before or after any other veterinary medicinal product therefore needs to be made by the responsible veterinarian on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision must be made whether to discontinue breast feeding or to discontinue/abstain from therapy.
Odločiti se je treba ali prenehati z dojenjem ali prenehati oz. vzdržati se zdravljenja.
A decision must be made whether to discontinue breast- feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Treba se je odločiti, ali naj se prekine dojenje ali naj se prekine zdravljenje z zdravilom LUMIGAN, pri tem pa je treba upoštevati koristi dojenja za otroka in koristi zdravljenja z zdravilom LUMIGAN za mater.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Abilify Maintena therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Abilify Maintena, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Desloratadine Teva 5 mg film-coated tablets therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Desloratadin Teva, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja s filgrastimom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z glicerol fenilbutiratom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from therapy.
Odločiti se je treba ali prenehati z dojenjem ali prenehati oz. vzdržati se zdravljenja.
A decision must be made whether to discontinue breast-feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Treba se je odločiti, ali naj se prekine dojenje ali naj se prekine zdravljenje z zdravilom LUMIGAN, pri tem pa je treba upoštevati koristi dojenja za otroka in koristi zdravljenja z zdravilom LUMIGAN za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue Incruse therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Incruse, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
A decision must be made whether to discontinue breast-feeding or to discontinue Nucala therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Nucala, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
A decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy to the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aranesp therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba ali za prenehanje dojenja ali za prekinitev/prenehanje zdravljenja z zdravilom Aranesp, z upoštevanjem koristi dojenja za otroka in koristi zdravljenja za žensko.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ATryn therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom ATryn, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZOPT therapy taking in to account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom AZOPT, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Filgrastim HEXAL therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem zdravljenja z zdravilom Filgrastim HEXAL, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja s filgrastimom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Fycompa, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from lumacaftor/ ivacaftor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom lumakaftor/ivakaftor, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neulasta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Neulasta, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rasilamlo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Rasilamlo, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Sivextro therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Sivextro, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with epoetin alfa taking into account the benefit of breastfeeding for the child and the benefit of epoetin alfa therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prekinitvijo/prenehanjem zdravljenja z epoetinom alfa, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja z epoetinom alfa za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zarzio therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem zdravljenja z zdravilom Zarzio, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEPATIER therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom ZEPATIER, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prekinitev/prenehanje zdravljenja z zdravilom Zinforo, upoštevaje koristi zdravljenja za žensko.
A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman.
Odločiti se je treba med prenehanjem dojenja in neuporabo cepiva ZOSTAVAX, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti cepljenja za mater.
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Airexar Spiromax, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision on whether to abstain from breast-feeding or to abstain from therapy with XGEVA should be made, taking into account the benefit of breast- feeding to the newborn/infant and the benefit of XGEVA therapy to the woman.
Odločiti se je treba, ali naj ženska neha dojiti ali naj preneha uporabljati zdravilo XGEVA, pri tem pa je treba upoštevati korist dojenja za novorojenčka/dojenčka in korist zdravljenja z zdravilom XGEVA za žensko.
A decision on whether to continue/discontinue breast- feeding or therapy with anidulafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of anidulafungin to the mother.
Pri odločitvi za nadaljevanje ali prekinitev dojenja oz. zdravljenja z anidulafunginom je treba upoštevati korist dojenja za otroka in korist zdravljenja z anidulafunginom za mater.
A decision on whether to continue/discontinue breast- feeding or to continue/discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Adult therapy to the woman.
Pri odločanju o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi cepljenja s cepivom Twinrix za odrasle je treba upoštevati tako korist dojenja za otroka kot korist cepljenja s cepivom Twinrix za odrasle za mater.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the woman.
Pri odločanju o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi zdravljenja z zdravilom Altargo je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja z zdravilom Altargo za mater.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with filgrastim should be made taking into account the benefit of breast- feeding to the child and the benefit of filgrastim therapy to the woman.
Odločitev o tem, ali naj mati nadaljuje/prekine z dojenjem ali naj nadaljuje/prekine zdravljenje s filgrastimom, je treba sprejeti glede na to, kakšne koristi ima dojenje za otroka oz. zdravljenje s filgrastimom za mater.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Renvela should be made taking into account the benefit of breast-feeding to the child and the benefit of Renvela therapy to the woman.
Odločitev o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi zdravljenja z zdravilom Renvela je treba sprejeti ob upoštevanju dejavnikov prednosti dojenja za otroka in prednosti terapije z zdravilom Renvela za bolnico.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Respreeza should be made, taking into account the benefit of breast-feeding to the child and the benefit of human alpha1- proteinase inhibitor therapy to the woman.
Odločitev o nadaljevanju/prenehanju dojenja ali nadaljevanju/prenehanju zdravljenja z zdravilom Respreeza je treba sprejeti ob upoštevanju dejavnikov prednosti dojenja za otroka in prednosti terapije s humanim zaviralcem alfa1-proteinaze za mater.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Sevelamer carbonate Zentiva should be made taking into account the benefit of breast-feeding to the child and the benefit of Sevelamer carbonate Zentiva therapy to the woman.
Odločitev o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi zdravljenja z zdravilom Sevelamer carbonate Zentiva je treba sprejeti ob upoštevanju dejavnikov prednosti dojenja za otroka in prednosti terapije z zdravilom Sevelamer carbonate Zentiva za bolnico.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with telavancin should be made taking into account the benefit of breastfeeding to the child and the benefit of telavancin therapy to the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja s telavancinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.